Abstract
This article describes recent advances in the development and biological evaluation of small molecule mGluR4 positive allosteric modulators (PAMs), and, to a lesser extent, orthosteric agonists. Due to its expression in the basal ganglia, the Family 3 GPCR metabotropic glutamate receptor subtype 4 (mGluR4) has recently garnered a great deal of attention as a putative target for the treatment of Parkinsons disease and a variety of other CNS disorders. Until 2008, with the exception of the prototypical mGluR4 PAM ( – )-PHCCC, very few small molecule tools existed to probe the role of selective activation of mGluR4. This review will focus on the explosion of novel mGluR4 PAMs reported in the past year and the further preclinical validation of mGluR4 activation as a potentially groundbreaking treatment for Parkinsons disease.
Keywords: Metabotropic, mGluR4, Parkinson's disease, allosteric, positive allosteric modulator, dopamine, PHCCC, glutamate
Current Topics in Medicinal Chemistry
Title: Recent Progress in the Development of mGluR4 Positive Allosteric Modulators for the Treatment of Parkinsons Disease
Volume: 9 Issue: 10
Author(s): Craig W. Lindsley, Colleen M. Niswender, Darren W. Engers and Corey R. Hopkins
Affiliation:
Keywords: Metabotropic, mGluR4, Parkinson's disease, allosteric, positive allosteric modulator, dopamine, PHCCC, glutamate
Abstract: This article describes recent advances in the development and biological evaluation of small molecule mGluR4 positive allosteric modulators (PAMs), and, to a lesser extent, orthosteric agonists. Due to its expression in the basal ganglia, the Family 3 GPCR metabotropic glutamate receptor subtype 4 (mGluR4) has recently garnered a great deal of attention as a putative target for the treatment of Parkinsons disease and a variety of other CNS disorders. Until 2008, with the exception of the prototypical mGluR4 PAM ( – )-PHCCC, very few small molecule tools existed to probe the role of selective activation of mGluR4. This review will focus on the explosion of novel mGluR4 PAMs reported in the past year and the further preclinical validation of mGluR4 activation as a potentially groundbreaking treatment for Parkinsons disease.
Export Options
About this article
Cite this article as:
Lindsley W. Craig, Niswender M. Colleen, Engers W. Darren and Hopkins R. Corey, Recent Progress in the Development of mGluR4 Positive Allosteric Modulators for the Treatment of Parkinsons Disease, Current Topics in Medicinal Chemistry 2009; 9 (10) . https://dx.doi.org/10.2174/156802609789378272
DOI https://dx.doi.org/10.2174/156802609789378272 |
Print ISSN 1568-0266 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4294 |
Call for Papers in Thematic Issues
Chemistry Based on Natural Products for Therapeutic Purposes
The development of new pharmaceuticals for a wide range of medical conditions has long relied on the identification of promising natural products (NPs). There are over sixty percent of cancer, infectious illness, and CNS disease medications that include an NP pharmacophore, according to the Food and Drug Administration. Since NP ...read more
Current Trends in Drug Discovery Based on Artificial Intelligence and Computer-Aided Drug Design
Drug development discovery has faced several challenges over the years. In fact, the evolution of classical approaches to modern methods using computational methods, or Computer-Aided Drug Design (CADD), has shown promising and essential results in any drug discovery campaign. Among these methods, molecular docking is one of the most notable ...read more
Drug Discovery in the Age of Artificial Intelligence
In the age of artificial intelligence (AI), we have witnessed a significant boom in AI techniques for drug discovery. AI techniques are increasingly integrated and accelerating the drug discovery process. These developments have not only attracted the attention of academia and industry but also raised important questions regarding the selection ...read more
From Biodiversity to Chemical Diversity: Focus of Flavonoids
Flavonoids are the largest group of polyphenols, plant secondary metabolites arising from the essential aromatic amino acid phenylalanine (or more rarely from tyrosine) via the phenylpropanoid pathway. The flavan nucleus is the basic 15-carbon skeleton of flavonoids (C6-C3-C6), which consists of two phenyl rings (A and B) and a heterocyclic ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Peptoids: Bio-Inspired Polymers as Potential Pharmaceuticals
Current Pharmaceutical Design Repetitive Ritalin Treatment Modulates the Diurnal Activity Pattern of Young SD Male Rats
Central Nervous System Agents in Medicinal Chemistry Nicotinamide: Oversight of Metabolic Dysfunction Through SIRT1, mTOR, and Clock Genes
Current Neurovascular Research Evaluation of Cytotoxic and Tyrosinase Inhibitory Activities of 2-phenoxy(thiomethyl) pyridotriazolopyrimidines: In Vitro and Molecular Docking Studies
Anti-Cancer Agents in Medicinal Chemistry Development and Validation of a Capillary Zone Electrophoresis Method for the Quantitative Determination of Atypical Antipsychotic Risperidone in Pharmaceutical Dosage forms
Current Analytical Chemistry Diagnosis and Management of Chronic Coronary Artery Disease
Current Cardiology Reviews Chromatin Remodeling, DNA Damage Repair and Aging
Current Genomics Structures Required of Polyphenols for Inhibiting Advanced Glycation end Products Formation
Current Drug Metabolism Cytochromes P450 in the Bioactivation of Chemicals
Current Topics in Medicinal Chemistry Epigenetics in Cystic Fibrosis: Epigenetic Targeting of a Genetic Disease
Current Drug Targets Development of Peptides as Potential Drugs for Cancer Therapy
Current Pharmaceutical Design 5-HT2 Receptors
Current Drug Targets - CNS & Neurological Disorders Pleiotropic Effects of Glucagon-like Peptide-1 (GLP-1)-Based Therapies on Vascular Complications in Diabetes
Current Pharmaceutical Design Biomarkers of Cell Damage Induced by Oxidative Stress in Parkinsons Disease and Related Models
Central Nervous System Agents in Medicinal Chemistry Accumulation of Intraneuronal Amyloid-β is Common in Normal Brain
Current Alzheimer Research MicroRNA Therapeutics in Neurological Disease
Current Pharmaceutical Design The Role of the Tyrosine Kinase Inhibitor STI571 in the Treatment of Cancer
Current Cancer Drug Targets Preventive and Protective Roles of Dietary Nrf2 Activators Against Central Nervous System Diseases
CNS & Neurological Disorders - Drug Targets The Animal Models of Dementia and Alzheimer’s Disease for Pre-Clinical Testing and Clinical Translation
Current Alzheimer Research Induction of Molecular Chaperones as a Therapeutic Strategy for the Polyglutamine Diseases
Current Pharmaceutical Biotechnology